Cinnabar Dandelion Cold Relief
- Manufacturer
- Uriel Pharmacy Inc
- Effective date
- 2009-12-31
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:09
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
Purpose
Uses: Temporarily relieves symptoms of cold, flu, sore throat.
Dosage & Administration
Directions: Take at first hint of symptoms. Dissolve under tongue. Take 4 times daily, up to every 1-2 hours as needed. Age 12 and older: 10 pellets. Ages 2-11: 5 pellets. Under age 2: ask a doctor.
OTC-Active Ingredient
Active Ingredients: Taraxacum e pl. tota 2X, Agropyrum e rad. 3X, Kali carb. e cinere Fagi 10X, Cinnabaris 20X, all HPUS.
Inactive Ingredient
Inactive Ingredient: Sucrose, Pyrite 3X.
Keep out of reach of children
KEEP OUT OF REACH OF CHILDREN.
Do not use section
Warnings:
Do not use if allergic to any ingredient. Do not use if safety seal is broken or missing.
Ask doctor section
Consult a doctor if symptoms are serious or persist for 3 days, if you are diabetic or intolerant of sugar.
Pregnancy or breast feeding section
If you are pregnant or nursing, consult a doctor before use.
Questions section
Principal Display Panel
Cinnabar Dandelion
Cold Relief
Homeopathic Pellets
net wt. 1 oz.
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 48951-3102-2 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-282c-f424-e053-dadaa90a57ce | Cinnabar Dandelion Cold Relief Pellets - 1 oz. |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-3102-2 | Cinnabar Dandelion Cold Relief | 1350 in 1 BOTTLE, GLASS | PELLET | 1350 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-3102 | CINNABAR DANDELION COLD RELIEF (TARAXACUM OFFICINALE ELYMUS REPENS ROOT POTASH MERCURIC SULFIDE) PELLET [URIEL PHARMACY INC] | 1 | Legacy NDC, 1 package rows | 20100120_483bf242-df66-11de-8a39-0800200c9a66.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ELYMUS REPENS ROOT | ACTIVE INGREDIENT | 3IXW0F6P8W | 1 | |
| MERCURIC SULFIDE | ACTIVE INGREDIENT | ZI0T668SF1 | 1 | |
| POTASH | ACTIVE INGREDIENT | BQN1B9B9HA | 1 | |
| TARAXACUM OFFICINALE | ACTIVE INGREDIENT | 39981FM375 | 1 | |
| ELYMUS REPENS ROOT | ACTIVE MOIETY | 3IXW0F6P8W | 1 | |
| MERCURIC CATION | ACTIVE MOIETY | ED30FJ8Y42 | 1 | |
| POTASH | ACTIVE MOIETY | BQN1B9B9HA | 1 | |
| TARAXACUM OFFICINALE | ACTIVE MOIETY | 39981FM375 | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Cinnabar Dandelion Cold Relief
- TARAXACUM OFFICINALE ELYMUS REPENS ROOT POTASH MERCURIC SULFIDE
- TARAXACUM OFFICINALE
- ELYMUS REPENS ROOT
- SUCROSE
- POTASH
- MERCURIC SULFIDE
- MERCURIC CATION
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-3102 | 48951-3102-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| TARAXACUM OFFICINALE | 39981FM375 | ACTIB |
| ELYMUS REPENS ROOT | 3IXW0F6P8W | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| POTASH | BQN1B9B9HA | ACTIB |
| MERCURIC SULFIDE | ZI0T668SF1 | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a8f9adb0-f62d-11de-8a39-0800200c9a66 | 483bf242-df66-11de-8a39-0800200c9a66 | 2009-12-31 | a8f9adb0-f62d-11de-8a39-0800200c9a66 483bf242-df66-11de-8a39-0800200c9a66 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
